Allarity Therapeutics Stock (NASDAQ:ALLR)

Ownership Financials Chart

Previous Close

$1.39

52W Range

$0.61 - $2.35

50D Avg

$1.52

200D Avg

$1.13

Market Cap

$19.58M

Avg Vol (3M)

$7.01M

Beta

0.22

Div Yield

ALLR Company Profile

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Dec 21, 2021

Website

ALLR Performance

ALLR Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-27.24M	$-17.93M	$-34.46M
Net Income	$-24.52M	$-11.90M	$-16.06M
EBITDA	$-27.24M	$-12.08M	$-17.24M
Basic EPS	-	$-0.01	$-1.86M
Diluted EPS	-	$-0.01	$-1.86M

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
RLYB	Rallybio Corporation
BCTX	BriaCell Therapeutics Corp.
APLM	Apollomics, Inc.
PASG	Passage Bio, Inc.
SABS	SAB Biotherapeutics, Inc.
GNPX	Genprex, Inc.
CING	Cingulate Inc.